ANNX Annexon Biosciences Inc. Net earnings per share for the last 12 months

Official company branding of Annexon Biosciences (ANNX)

Intellectual property protection via antibody patents creates a high barrier to entry for competitors, providing Annexon, Inc. (ANNX) with strong market power due to its unique method of blocking the C1q protein. The change in rolling net income per share visualizes this correlation, where -1.02 shows the value of this parameter. However, the absence of commercial products necessitates a period of planned capital burn for research.

ANNX Annexon, Inc. Net earnings per one share for the last twelve months (07/04/2022 - 11/14/2026)

Analytical breakdowns for Annexon Inc. (ANNX)

- stock price and consensus target price:
Stock Price Annexon Biosciences Inc.|ANNX - Average Forecast Price
- market capitalization data:
Market Valuation Annexon|ANNX - Business Value
- balance sheet net asset value indicators:
Net Assets per Single Share Annexon|ANNX - Total Stockholders' Equity|Market Value to Book Value Ratio annexonbio.com|ANNX - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Annexon, Inc.|ANNX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital annexonbio.com|ANNX - Company Total Debt Obligations|Debt to Book Capitalization Ratio Annexon|ANNX - Company Long-Term Indebtedness|Company Short-Term Debts Annexon|Quick Liquidity Indicator annexonbio.com
- earnings and multiples data:
ANNX - Net Financial Result|Projected Future Earnings Annexon, Inc.|ANNX - P/E Multiple|Future Price to Earnings Annexon, Inc.|ANNX - Growth-Adjusted P/E Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Annexon|ANNX - Operating profit before amortization|Net earnings per share for the last 12 months Annexon|ANNX - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months annexonbio.com|ANNX - Earnings per share growth this year|Earnings growth forecast for next year Annexon, Inc.
- revenue and sales proceeds data:
ANNX - Company Total Revenue|Company Future Sales Volume annexonbio.com|ANNX - P/S Multiple|Price-to-Projected Revenue Ratio Annexon Biosciences Inc.
Fundamental company analysis:ANNX - Annexon Inc.
Flagship merchandise of Annexon Biosciences

Annexon, Inc. focuses on developing innovative therapies for neurodegenerative pathologies by blocking the C1q protein to protect neural connections. The current value of -1.02 reflects the net income allocated per share for the year, allowing for an assessment of the business's actual profitability by analyzing the fundamental EPS TTM metric for sustainable growth or the risk of asset overvaluation.

Direct competitors

biogen.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year NBIX (Neurocrine)|RGC: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Axsome Therapeutics Inc|ACAD (ACADIA Corp) - Net earnings per share (EPS TTM)|XENE: Earnings per share for the trailing year|Net earnings per share for the last 12 months VKTX (Viking Therapeutics, Inc.)|Net earnings per share (EPS TTM) Supernus Pharmaceuticals, Inc. (SUPN)|Catalyst Pharmaceuticals, Inc. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters DNLI (Denali Therapeutics Inc)|Harmony Biosciences - Net earnings per share (EPS TTM)|Earnings per share for the trailing year BHVN (biohavenpharma.com)|AMLX: Net earnings per share (EPS TTM)|Trevi Therapeutics, Inc. - Earnings per share for the trailing year|PRAX (Praxis Corp) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Anavex Life Sciences AVXL|Net earnings per share (EPS TTM) CBLL|PRTA (prothena.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) ALEC (Alector Inc.)|Earnings per share for the trailing year OMER|NGNE: Net earnings per share for the last 12 months|ACIU (AC Immune Corp) - Earnings per share for the last 12 months|VYGR: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Neumora Therapeutics, Inc. (NMRA)|SCLX (Scilex Holding) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months TVGN (Tevogen Bio)|Net earnings per share (EPS TTM) ACOG|CGTX - Net earnings per one share for the last twelve months|Inhibikase Pharma - Net earnings per share for the last 12 months|Net earnings per share for the last four quarters cassavasciences.com (SAVA)|Assertio Holdings - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Coya Therapeutics COYA|VTGN: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months OVID|Earnings per share for the last twelve months Acumen Pharmaceuticals|CRVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATHE|CLNN - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months PepGen Inc PEPG|Net earnings per share for the last four quarters jupiterneurosciences.com (JUNS)|Relmada Therapeutics, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ANVS (annovisbio.com)|Grace Tx (GRCE) - Earnings per share for the last twelve months|Firefly Neuroscience (AIFF) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Klotho Neurosciences Inc|neurosense-tx.com (NRSN) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Reviva Pharmaceuticals Holdings, Inc. (RVPH)|Net earnings per share (EPS TTM) MetaVia, Inc. (MTVA)|NeurAxis, Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Helius Medical HSDT|PASG - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Neuphoria Therapeutics, Inc.|Minerva Neurosciences Inc (NERV) - Earnings per share for the last twelve months|Athira Pharma, Inc. - Earnings per share for the trailing year|ADXN (Addex) - Net earnings per share (EPS TTM)|Alzamend Neuro, Inc. - Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) CYCN|PTIX - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months pasitheaclinics.com KTTA|Earnings per share for the trailing year CRGT|Avenue Therapeutics Inc - Net earnings per share (EPS TTM)|Brainstorm Cell Therapeutics, Inc. (BCLI) - Net earnings per share for the last 12 months|CARA: Net earnings per share (EPS TTM)|Chromocell - Earnings per share for the trailing year|ELYM (Eliem Therapeutics, Inc.) - Net earnings per share (EPS TTM)|ITCI (intracellulartherapies.com) - Earnings per share for the last four quarters|Earnings per share for the last twelve months Longboard Pharma (LBPH)|Marinus - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) NKGN (nkgenbiotech.com)|NeuroBo Pharma - Earnings per share for the last twelve months|Sage Therapeutics Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year SNPX (Synaptogenix, Inc.)|TRVN (trevena.com) - Net earnings per share for the last 12 months|Net earnings per share for the last 12 months Vigil Neuroscience Inc.|Earnings per share for the last twelve months Anew Medical|CERE: Earnings per share for the trailing year